Aura Biosciences, Inc.
NASDAQ:AURABiotechnology
-$0.09 today
- Market cap
- $744.13M
- Beta
- 0.39
- P/E (TTM)
- -3.7
- EPS (TTM)
- -$1.67
Volume 0.63M
Average 0.52M
Returns on capital
Aura Biosciences, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-77.6%
avg -59.3%
ROIC
-73.1%
avg -58.2%
ROA
-62.7%
avg -50.6%
Analysis
ROA is currently the strongest return metric at -62.7% versus its period average of -50.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Jill Hopkins | Chief Medical Officer & President of Research and Development | USD 792.75K | 61 | — | — |
Susan Abu-Absi | Chief Operating Officer | USD 592.5K | — | 134.51K | 0.21% |
Alex Dasalla | Head of Investor Relations & Corporate Communications | — | — | — | — |
Anthony Daniels | Vice President & Therapeutic Area of Head Ocular Oncology | — | — | — | — |
Patrick Nealon | Senior Vice President of Clinical Development Operations | — | — | — | — |
Amy Elazzouzi | Senior Vice President of Finance, Treasurer and Secretary | — | 52 | 46.46K | 0.07% |
Erica Kratz | Chief Regulatory & Quality Officer | — | — | 100.89K | 0.16% |
Julie Person | Chief People Officer | — | 52 | 107.61K | 0.17% |
Natalie C. Holles | President, CEO & Director | — | 53 | 600.12K | 0.93% |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 1, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
10
$39.83M
Net Transaction Value
−$39.83M
Net selling
Most Active
Kilroy Conor
2 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Jun 16, 26Jun 16, 2026 | Gibney Anthony S Direct | Sell | $82.3K$82,330.08 |
| May 7, 26May 7, 2026 | Matrix Capital Management Company, LP Indirect | Sell | $39M$39,044,986.80 |
| Apr 16, 26Apr 16, 2026 | Kilroy Conor Direct | Sell | $82.4K$82,400.76 |
| Feb 17, 26Feb 17, 2026 | Kilroy Conor Direct | Sell | $61K$60,998.95 |
| Feb 17, 26Feb 17, 2026 | Plavsic Mark Direct | Sell | $80.2K$80,244.50 |
| Feb 17, 26Feb 17, 2026 | Hopkins Janet Jill Direct | Sell | $103.2K$103,229.06 |
| Feb 17, 26Feb 17, 2026 | Elazzouzi Amy Direct | Sell | $43.3K$43,257.94 |
| Feb 17, 26Feb 17, 2026 | de los Pinos Elisabet Direct | Sell | $241.1K$241,098.88 |
| Jan 20, 26Jan 20, 2026 | Elazzouzi Amy Direct | Sell | $7.7K$7,683.66 |
| Jan 20, 26Jan 20, 2026 | de los Pinos Elisabet Direct | Sell | $82.3K$82,270.08 |
Summary
Insiders reported 0 buys worth $0.00 and 10 sells worth $39.83M over the last 12 months. That adds up to net selling of $39.83M. Kilroy Conor was the most active insider with 2 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Aura Biosciences, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about AURA's management, answered from reported figures.
Who manages AURA?
Aura Biosciences, Inc. (AURA) lists 9 active executives. The top listed executive is Alex Dasalla, Head of Investor Relations & Corporate Communications.
Are AURA insiders buying or selling?
Recent insider activity shows net buying of $30.32M.
Continue the stock analysis
Jump to another research area for this company.